Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Glenmark makes and sells generic, branded, and specialty medicines to patients in more than 80 countries.
Glenmark is a drugmaker. It sells medicines — mostly cheap copies of drugs whose patents have expired, plus its own branded versions and a growing lineup of specialty products — to patients in over 80 countries. If you've ever filled a prescription with a generic pill, you've used the kind of business Glenmark runs: it develops a medicine, gets it approved by regulators, manufactures it, and sells it through pharmacies and hospitals, usually at a fraction of the price of the original brand.
The business splits into a few pieces. Generics and branded generics are the bread and butter: high-volume pills sold in India, Europe, and the US, where Glenmark competes on price and manufacturing scale against giants like Sun Pharma and Dr. Reddy's Laboratories. Then there's the specialty arm, which is the interesting bet. Instead of selling commodity pills, Glenmark develops its own patented drugs — mainly in dermatology and respiratory care — and sells them in the US and Europe at brand-name prices. That's a much harder, slower, riskier game, but the margins are far better than generic pills. India is Glenmark's home market and a big profit engine, because branded generics there sell at premium prices and doctors build loyalty to familiar names. The US is the biggest prize but also the most brutal: generic prices there have been falling for years, and Glenmark, like its peers, has had to fight for every dollar. The company has also built manufacturing plants in India and abroad, and it invests heavily in research — both to file new generic drug applications and to push its specialty pipeline forward.
The company is headquartered near Mumbai. It is controlled by the Saldanha family, and founder Glenn Saldanha still runs it. Glenmark's big swing in recent years has been specialty drugs: it has poured money into developing its own molecules rather than just copying others, which is a bet that it can escape the generic price war. That bet is expensive and uncertain, but it's the main thing that separates Glenmark from a plain-vanilla pill maker. The company also out-licenses some of its molecules to bigger partners, collecting milestone payments and royalties — a way to earn money from research without paying for the whole launch itself.
Saved answer · last researched 16 Nov 2026